Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of ABCB5-positive mesenchymal stromal cells in epidermolysis bullosa
2022-500266-10-00Phase 3Completed
- Sponsor
- RHEACELL
- Start
- Jun 2023
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in Recessive Dystrophic Epidermolysis Bullosa (RDEB) and junctional epidermolysis bullosa (JEB) comparing ABCB5+ MSCs with Placebo (2 arms). Started Jun 2023; status: completed.
02
Drugs
EBESANAR
03
Conditions
Recessive Dystrophic Epidermolysis Bullosa (RDEB)junctional epidermolysis bullosa (JEB)
Beyond the preview
Go deeper on 2022-500266-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500266-10-00.